| Name | Title | Contact Details |
|---|
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
Sustainable Bioproducts has developed a breakthrough protein production platform for a variety of consumer and industrial applications.
Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs